| Antidepressants on multiple sclerosis: a review of in vitro and in vivo models E Stamoula, S Siafis, I Dardalas, A Ainatzoglou, A Matsas, T Athanasiadis, ... Frontiers in Immunology 12, 677879, 2021 | 28 | 2021 |
| mRNA in the context of protein replacement therapy T Vavilis, E Stamoula, A Ainatzoglou, A Sachinidis, M Lamprinou, ... Pharmaceutics 15 (1), 166, 2023 | 26 | 2023 |
| Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine: real-world evidence from Greek healthcare workers K Kontopoulou, A Ainatzoglou, A Ifantidou, CT Nakas, G Gkounti, ... Journal of medical microbiology 70 (8), 001387, 2021 | 18 | 2021 |
| Atypical antipsychotics in multiple sclerosis: A review of their in vivo immunomodulatory effects Ε Stamoula, A Ainatzoglou, VP Stamatellos, I Dardalas, S Siafis, A Matsas, ... Multiple Sclerosis and Related Disorders 58, 103522, 2022 | 15 | 2022 |
| Prevalence of post-menopausal depression and associated factors: A web-based cross-sectional study in Greece G Papazisis, I Tsakiridis, A Ainatzoglou, A Pappa, T Bellali, D Kouvelas, ... Maturitas 156, 12-17, 2022 | 9 | 2022 |
| Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive K Kontopoulou, A Ainatzoglou, CT Nakas, A Ifantidou, G Goudi, ... Vaccine 39 (36), 5078-5081, 2021 | 9 | 2021 |
| The Effects of PDE Inhibitors on Multiple Sclerosis: a Review of in vitro and in vivo Models A Ainatzoglou, E Stamoula, I Dardalas, S Siafis, G Papazisis Current Pharmaceutical Design 27 (20), 2387-2397, 2021 | 4 | 2021 |
| Serum Proteome Signatures of Anti-SARS-CoV-2 Vaccinated Healthcare Workers in Greece Associated with Their Prior Infection Status E Stamoula, E Sarantidi, V Dimakopoulos, A Ainatzoglou, I Dardalas, ... International Journal of Molecular Sciences 23 (17), 10153, 2022 | 3 | 2022 |
| Immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in elderly people over 85 years of age in Greece: the GREVAXIMO study K Kontopoulou, CT Nakas, A Ainatzoglou, A Ifantidou, P Ntotsi, ... Aging clinical and experimental research 33, 3385-3389, 2021 | 3 | 2021 |
| Egg White and Yolk Protein Atlas: New Protein Insights of a Global Landmark Food E Sarantidi, A Ainatzoglou, C Papadimitriou, E Stamoula, K Maghiorou, ... Foods 12 (18), 3470, 2023 | 2 | 2023 |
| Second dose of the BNT162b2 mRNA vaccine in Greece: the value of timely administration K Kontopoulou, A Ainatzoglou, C Nakas, A Ifantidou, G Goudi, ... Available at SSRN 3800040, 2021 | 2 | 2021 |
| mRNA in the Context of Protein Replacement Therapy. Pharmaceutics 2023, 15, 166 T Vavilis, E Stamoula, A Ainatzoglou, A Sachinidis, M Lamprinou, ... | 1 | 2023 |
| Evolution of Antibody Titers Up to 6 Months Post-Immunization with the BNT162b2 Pfizer/BioNTech Vaccine in Greece K Kontopoulou, C Nakas, A Ainatzoglou, G Goudi, C Katsioulis, ... BioNTech Vaccine in Greece (September 12, 2021), 2021 | 1 | 2021 |
| Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in elderly people over 85 years of age in Greece K Kontopoulou, C Nakas, A Ainatzoglou, A Ifantidou, G Goudi, P Ntotsi, ... Available at SSRN 3850394, 2021 | 1 | 2021 |
| Lung Cancer Proteogenomics: Shaping the Future of Clinical Investigation T Vavilis, ML Petre, G Vatsellas, A Ainatzoglou, E Stamoula, A Sachinidis, ... Cancers 16 (6), 1236, 2024 | | 2024 |
| Lung Cancer Proteogenomics: Shaping the Future of Clinical Investigation ML Petre, T Vavilis, G Vatsellas, A Ainatzoglou, E Stamoula, A Sachinidis, ... OSF, 2024 | | 2024 |
| Effects of GABAergic Agents on Multiple Sclerosis. A Narrative Review of In-vivo Models Е Stamoula, A Ainatzoglou, I Dardalas, T Vavilis, VP Stamatellos, S Siafis, ... CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2024 | | 2024 |
| Next generation sequencing in toxicology T Vavilis, E Stamoula, A Sachinidis, M Lamprinou, I Dardalas, ... Elsevier, 2023 | | 2023 |
| Omics and related recent technologies A Ainatzoglou, T Vavilis, E Stamoula, A Sachinidis, M Lamprinou, ... Elsevier, 2023 | | 2023 |
| Effects of GABAergic agents on Multiple Sclerosis. A narrative review of in-vivo models. A Ainatzoglou, I Dardalas, T Vavilis, VP Stamatellos, S Siafis, T Psathas, ... CNS & Neurological Disorders Drug Targets, 2022 | | 2022 |
